Tag: Starpharma
Starpharma: Receives $7.1m R&D tax incentive refund
Starpharma Receives $7.1m R&D tax incentive refundBiopharmaceutical company Starpharma (SPL) receives a $7.1 million research and development tax...
Starpharma: Registers VIRALEZE nasal spray in Indonesia
Starpharma Registers VIRALEZE nasal spray in IndonesiaStarpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining...
Starpharma: Spends September quarter progressing DEP technology
Starpharma Spends September quarter progressing DEP technologyStarpharma (SPL) spent the September quarter progressing its DEP technology and signing...
Starpharma: Expands research program with Genentech
Starpharma Expands research program with GenentechStarpharma (SPL) expands its research agreement with Genentech for its drug delivery technology,...
Starpharma: Receives $7.7m R&D tax refund
Starpharma Receives $7.7m R&D tax refundStarpharma (SPL) receives a $7.7 million research and development tax incentive refund
The...
Starpharma: Continues VIRALEZE success in December quarter
Starpharma Continues VIRALEZE success in December quarterStarpharma (SPL) releases its September quarterly report, with the period again highlighted...
Starpharma: Advances progress for COVID-19 nasal spray
During the September quarter, Starpharma (SPL) achieved several milestones with its SPL7013 COVID-19 nasal spray
Additionally, the pharmaceutical...
Starpharma: Raises $45M for next phase of growth
Pharmaceutical company Starpharma (SPL) has raised $45 million via an oversubscribed share placement
All up, 30 million new...
Starpharma: Receives $1M MRFF funding for COVID-19 nasal spray
Starpharma (SPL) has been awarded $1M in matched funding by the Australian Government's Medical Research Future Fund (MRFF)
...
Starpharma: Updates market on nasal spray
Starpharma has provided updates on its COVID-19 nasal protection spray, which uses antiviral dendrimer SPL7013
Already the company...